Exosome Dx Aiming to Commercialize Liquid Biopsies Seeks 25M

January 28, 2015 | Cambridge, MA-based Exosome Diagnostics aims to raise $25 million, on top of the $27 million in Series B funding it raised last March. Exosome would use the cash to launch its first two products: a blood-based test for lung cancer, and a urine test for prostate cancer. Xconomy